Inhibitor Therapeutics (INTI) EPS (Basic) (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly EPS (Basic) came in at -$0.01 in Q1 2026, down 37.69% YoY from -$0.01 in Q1 2025, and up 32.14% on a QoQ basis from -$0.01 in Q4 2025.
Inhibitor Therapeutics (INTI) EPS (Basic) (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of EPS (Basic) data on file, last reported at -$0.01 in Q1 2026.
- Quarterly EPS (Basic) fell 37.69% year-over-year to -$0.01 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.02 (down 2.91% YoY) and the FY2025 annual result came in at -$0.02, up 1.43% from the prior year.
- EPS (Basic) rose to -$0.01 in Q1 2026, from -$0.01 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $0.03 in Q4 2022 to a low of -$0.01 in Q4 2024.
- A 5-year average of -$0.0 and a median of -$0.0 in 2023 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) soared 15175.94% — and 2023, when it tumbled 1036.9%.
- Tracing INTI's EPS (Basic) over 5 years: stood at $0.03 in 2022, then slumped by 120.18% to -$0.01 in 2023, then dropped by 24.43% to -$0.01 in 2024, then rose by 10.38% to -$0.01 in 2025, then surged by 32.14% to -$0.01 in 2026.
- The last three EPS (Basic) figures came in at -$0.01 (Q1 2026), -$0.01 (Q4 2025), and -$0.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.01 |
| Dec 31, 2025 | -0.01 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | -0.01 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | -0.01 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 0.03 |
| Sep 30, 2022 | 0.00 |
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.00 |